---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000106"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T02:59:53.516977+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025

## Summary
- CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.
- Separation agreement signed Oct 20, 2025 provides 12 months salary and pro-rated bonus eligibility.
- Dr. Jewell releases all claims against the company in exchange for severance benefits.

## SEC filing metadata
- accession: 0001453687-25-000106
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000106/0001453687-25-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000106/rnac-20251015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000106
- JSON: https://secwatch.observer/filing/0001453687-25-000106.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.